Global Letermovir API Market Research Report 2024

Publication ID:

PB511240125

Publication Date:

November 1, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Letermovir API refers to the active pharmaceutical ingredient in Letermovir, an antiviral medication used primarily for the prevention of cytomegalovirus (CMV) infection in adult transplant recipients.The drug is administered orally or intravenously.
The global Letermovir API market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Letermovir API is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Letermovir API is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Letermovir API include Shandong Chenghui Shuangda Pharmaceutical, Jinan Tantu Chemicals, Zydus Lifesciences, Lupin, Metrochem API, Alembic Pharmaceuticals, Charioteer, Olon, Teva API, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Letermovir API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Letermovir API.
The Letermovir API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Letermovir API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Letermovir API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Shandong Chenghui Shuangda Pharmaceutical
Jinan Tantu Chemicals
Zydus Lifesciences
Lupin
Metrochem API
Alembic Pharmaceuticals
Charioteer
Olon
Teva API
Segment by Type
Purity 鈮� 98%
Purity 鈮� 99%
Segment by Application
Tablets
Injections
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Letermovir API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Letermovir API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Letermovir API Market Overview
1.1 Product Definition
1.2 Letermovir API by Type
1.2.1 Global Letermovir API Market Value Comparison by Type (2024-2030)
1.2.2 Purity 鈮� 98%
1.2.3 Purity 鈮� 99%
1.3 Letermovir API by Application
1.3.1 Global Letermovir API Market Value by Application (2024-2030)
1.3.2 Tablets
1.3.3 Injections
1.4 Global Letermovir API Market Size Estimates and Forecasts
1.4.1 Global Letermovir API Revenue 2019-2030
1.4.2 Global Letermovir API Sales 2019-2030
1.4.3 Global Letermovir API Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Letermovir API Market Competition by Manufacturers
2.1 Global Letermovir API Sales Market Share by Manufacturers (2019-2024)
2.2 Global Letermovir API Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Letermovir API Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Letermovir API, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Letermovir API, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Letermovir API, Product Type & Application
2.7 Global Key Manufacturers of Letermovir API, Date of Enter into This Industry
2.8 Global Letermovir API Market Competitive Situation and Trends
2.8.1 Global Letermovir API Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Letermovir API Players Market Share by Revenue
2.8.3 Global Letermovir API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Letermovir API Market Scenario by Region
3.1 Global Letermovir API Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Letermovir API Sales by Region: 2019-2030
3.2.1 Global Letermovir API Sales by Region: 2019-2024
3.2.2 Global Letermovir API Sales by Region: 2025-2030
3.3 Global Letermovir API Revenue by Region: 2019-2030
3.3.1 Global Letermovir API Revenue by Region: 2019-2024
3.3.2 Global Letermovir API Revenue by Region: 2025-2030
3.4 North America Letermovir API Market Facts & Figures by Country
3.4.1 North America Letermovir API Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Letermovir API Sales by Country (2019-2030)
3.4.3 North America Letermovir API Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Letermovir API Market Facts & Figures by Country
3.5.1 Europe Letermovir API Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Letermovir API Sales by Country (2019-2030)
3.5.3 Europe Letermovir API Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Letermovir API Market Facts & Figures by Region
3.6.1 Asia Pacific Letermovir API Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Letermovir API Sales by Region (2019-2030)
3.6.3 Asia Pacific Letermovir API Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Letermovir API Market Facts & Figures by Country
3.7.1 Latin America Letermovir API Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Letermovir API Sales by Country (2019-2030)
3.7.3 Latin America Letermovir API Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Letermovir API Market Facts & Figures by Country
3.8.1 Middle East and Africa Letermovir API Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Letermovir API Sales by Country (2019-2030)
3.8.3 Middle East and Africa Letermovir API Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Letermovir API Sales by Type (2019-2030)
4.1.1 Global Letermovir API Sales by Type (2019-2024)
4.1.2 Global Letermovir API Sales by Type (2025-2030)
4.1.3 Global Letermovir API Sales Market Share by Type (2019-2030)
4.2 Global Letermovir API Revenue by Type (2019-2030)
4.2.1 Global Letermovir API Revenue by Type (2019-2024)
4.2.2 Global Letermovir API Revenue by Type (2025-2030)
4.2.3 Global Letermovir API Revenue Market Share by Type (2019-2030)
4.3 Global Letermovir API Price by Type (2019-2030)
5 Segment by Application
5.1 Global Letermovir API Sales by Application (2019-2030)
5.1.1 Global Letermovir API Sales by Application (2019-2024)
5.1.2 Global Letermovir API Sales by Application (2025-2030)
5.1.3 Global Letermovir API Sales Market Share by Application (2019-2030)
5.2 Global Letermovir API Revenue by Application (2019-2030)
5.2.1 Global Letermovir API Revenue by Application (2019-2024)
5.2.2 Global Letermovir API Revenue by Application (2025-2030)
5.2.3 Global Letermovir API Revenue Market Share by Application (2019-2030)
5.3 Global Letermovir API Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Shandong Chenghui Shuangda Pharmaceutical
6.1.1 Shandong Chenghui Shuangda Pharmaceutical Company Information
6.1.2 Shandong Chenghui Shuangda Pharmaceutical Description and Business Overview
6.1.3 Shandong Chenghui Shuangda Pharmaceutical Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Shandong Chenghui Shuangda Pharmaceutical Letermovir API Product Portfolio
6.1.5 Shandong Chenghui Shuangda Pharmaceutical Recent Developments/Updates
6.2 Jinan Tantu Chemicals
6.2.1 Jinan Tantu Chemicals Company Information
6.2.2 Jinan Tantu Chemicals Description and Business Overview
6.2.3 Jinan Tantu Chemicals Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Jinan Tantu Chemicals Letermovir API Product Portfolio
6.2.5 Jinan Tantu Chemicals Recent Developments/Updates
6.3 Zydus Lifesciences
6.3.1 Zydus Lifesciences Company Information
6.3.2 Zydus Lifesciences Description and Business Overview
6.3.3 Zydus Lifesciences Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Zydus Lifesciences Letermovir API Product Portfolio
6.3.5 Zydus Lifesciences Recent Developments/Updates
6.4 Lupin
6.4.1 Lupin Company Information
6.4.2 Lupin Description and Business Overview
6.4.3 Lupin Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Lupin Letermovir API Product Portfolio
6.4.5 Lupin Recent Developments/Updates
6.5 Metrochem API
6.5.1 Metrochem API Company Information
6.5.2 Metrochem API Description and Business Overview
6.5.3 Metrochem API Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Metrochem API Letermovir API Product Portfolio
6.5.5 Metrochem API Recent Developments/Updates
6.6 Alembic Pharmaceuticals
6.6.1 Alembic Pharmaceuticals Company Information
6.6.2 Alembic Pharmaceuticals Description and Business Overview
6.6.3 Alembic Pharmaceuticals Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Alembic Pharmaceuticals Letermovir API Product Portfolio
6.6.5 Alembic Pharmaceuticals Recent Developments/Updates
6.7 Charioteer
6.7.1 Charioteer Company Information
6.7.2 Charioteer Description and Business Overview
6.7.3 Charioteer Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Charioteer Letermovir API Product Portfolio
6.7.5 Charioteer Recent Developments/Updates
6.8 Olon
6.8.1 Olon Company Information
6.8.2 Olon Description and Business Overview
6.8.3 Olon Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Olon Letermovir API Product Portfolio
6.8.5 Olon Recent Developments/Updates
6.9 Teva API
6.9.1 Teva API Company Information
6.9.2 Teva API Description and Business Overview
6.9.3 Teva API Letermovir API Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva API Letermovir API Product Portfolio
6.9.5 Teva API Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Letermovir API Industry Chain Analysis
7.2 Letermovir API Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Letermovir API Production Mode & Process
7.4 Letermovir API Sales and Marketing
7.4.1 Letermovir API Sales Channels
7.4.2 Letermovir API Distributors
7.5 Letermovir API Customers
8 Letermovir API Market Dynamics
8.1 Letermovir API Industry Trends
8.2 Letermovir API Market Drivers
8.3 Letermovir API Market Challenges
8.4 Letermovir API Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Shandong Chenghui Shuangda Pharmaceutical
Jinan Tantu Chemicals
Zydus Lifesciences
Lupin
Metrochem API
Alembic Pharmaceuticals
Charioteer
Olon
Teva API

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂